Hospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (59)

2023

  1. Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival

    Clinical and experimental rheumatology, Vol. 41, Núm. 8, pp. 1695-1703

  2. The complex HLA-E-nonapeptide in Behçet disease

    Frontiers in Immunology, Vol. 14

2022

  1. Anti–Polymyositis/Scl Antibodies in Systemic Sclerosis Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature

    Journal of Clinical Rheumatology, Vol. 28, Núm. 1, pp. E180-E188

  2. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  3. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  4. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  5. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

    Scientific reports, Vol. 12, Núm. 1, pp. 5289

  6. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry

    Seminars in Arthritis and Rheumatism, Vol. 55

  7. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

    Autoimmunity Reviews, Vol. 21, Núm. 10

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  4. Multiple vertebral fractures after suspension of denosumab. A series of 56 cases

    International Journal of Clinical Practice, Vol. 75, Núm. 10

  5. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  6. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)

    Rheumatology (Oxford, England), Vol. 60, Núm. 2, pp. 872-880

  7. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Longterm efficacy and safety of monotherapy versus combination therapy in systemic sclerosis-associated pulmonary arterial hypertension: A retrospective RESCLE registry study

    Journal of Rheumatology, Vol. 47, Núm. 1, pp. 89-98

  3. Serodiscordant patients with systemic sclerosis: When antibody does not correspond to skin involvement

    Clinical and Experimental Rheumatology, Vol. 38, pp. S106-S114

  4. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

    Autoimmunity Reviews, Vol. 19, Núm. 5